XAIR

Beyond Air, Inc. (XAIR) | Rumor.io

Beyond Air

XAIR

Attention (50-day avg)0%

Attention rank (50-day avg)#1,729

Bullish sentiment (50-day avg)55%

Price to earnings ratio0.01

Market capitalization2.5M

Earnings per share-60.5

Dividend yield (TTM)—

Revenue (annual)7.7M

Net income (annual)-34.3M

Social

What share of all stock conversation is about XAIR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% +0	0% 0

Sep 1

Beyond Air, Inc.'s (XAIR) LungFit GO has been granted Breakthrough Device Designation by the U.S. FDA for treating nontuberculous mycobacterial pulmonary disease.
The company's low float has raised concerns, with some speculating it may lead to a significant price drop.
There is ongoing discussion about the potential dilution of shares and the impact of warrants, with some investors predicting a price under $1.00.

Generated by AI

Sentiment

Of the messages about XAIR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	40%	50.53% -9.97	73.38% -2.1
Bearish	—	60%	49.47% +9.97	26.62% +2.1

Bullish· Aug 31

The FDA approval of Beyond Air, Inc. (XAIR) is a significant news event that could trigger a reversal and a subsequent price increase.
The asset has seen a trend reversal, with big investors coming in and algos accumulating shares, indicating a strong uptrend.
The company's stock price is expected to reach $9 or higher, with some predictions as high as $11, driven by funds buying and short covering.

Bearish· Aug 31

The company's stock price has dropped significantly despite positive news, including a FDA announcement, and the author believes this is a result of intentional dilution.
The company's dilution of shares, including millions of warrants, has been identified as a major red flag, and the author believes this is a scam to manipulate the stock price.
The company's stock has been shorted despite positive news, and the author believes this is a sign of the market's distrust in the company's fundamentals, with the stock experiencing a 52-week low.

Generated by AI

Topics

Of the messages about XAIR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	71.43%	30.3%	16.54%
Technical Analysis	—	28.57%	69.7%	33.69%
Analysts	—	0%	0%	23.14%
Controversies	—	0%	0%	1.06%
Earnings	—	0%	0%	0.68%
Macro	—	0%	0%	24.89%

Announcements· Jan 14

Beyond Air, Inc. announced the sale of 85% of its subsidiary NeuroNOS, a developer of a groundbreaking medical treatment, for $36 million.
Beyond Air received FDA approval and CE Mark for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure.
Beyond Air announced a $5.0 million private placement of 3,930,818 shares and warrants at a combined price of $1.272 per share, priced at-the-market under Nasdaq rules.

Technical Analysis· Jan 14

The technical analysis suggests that Beyond Air, Inc. ($XAIR) is in a long-term downtrend, with a parabolic squeeze off lows and extremely stretched momentum, indicating a high risk of mean reversion.
The stock has shown a significant vertical move, with a 150% increase on high relative volume, suggesting a massive institutional accumulation phase and a potential structural trend shift.
The 1-hour chart for $XAIR has confirmed a Wave 5 correction, with a potential base forming before a potential Wave (b) relief toward $2.13, and the stock is technically oversold with a golden cross on the 5-minute chart.

Generated by AI

Community

Of the messages about XAIR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	28%	41.03%	15.24%
Newcomers	—	72%	58.97%	84.76%

Regulars· Aug 31

The FDA Breakthrough Device Designation for LungFit GO to treat Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) has been a significant catalyst for the stock, with many regular participants noting its importance.
Several participants have expressed their bullish sentiments on the stock, with some even initiating or re-initiating their buy positions, citing the company's potential for growth.
The stock has been subject to short selling and volatility, with some participants warning others to sell the "pops" and buy the dips, rather than chasing the stock's price movements.

Newcomers· Aug 31

Many newcomers are optimistic about Beyond Air, Inc. (XAIR), with some predicting a significant price increase after a positive press release.
Some newcomers believe that XAIR's recent price drop is a buying opportunity, with one user predicting a reversal and another stating that major news will drive the stock up.
However, others are skeptical, pointing out concerns such as the company's history of losses, lack of FDA approval, and potential dilution from resale shares and warrants.

Generated by AI

GARDEN CITY, N.Y., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients' lives, today announced that its management team will participate in the 2026 Cantor Global Healthcare Conference, which is being held at the Waldorf Astoria New York, New York on September 9-11, 2026. Fireside Chat Details:Date: Thursday, September 10thTime: 3:55 PM EDT Webc

28d agoYahoo Finance

Beyond Air® Receives FDA Breakthrough Device Designation for LungFit® GO to Treat Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD)

1mo agoYahoo Finance

Beyond Air to sell NeuroNOS stake to Univo for 19.99% equity

1mo agoInvesting.com

Beyond Air Enters Definitive Agreement to Sell Its NeuroNOS Stake to UNIVO Pharmaceutical Industries in Exchange for Equity and Milestone Payments

Beyond Air to receive shares representing 19.99% of Univo's issued and outstanding share capital upon closing Beyond Air eligible to receive up to $32.5 million in development and commercial milestone payments GARDEN CITY, N.Y., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) today announced that they have entered into a definitive agreement under which UNIVO Pharmaceutical Industries Ltd (“UNIVO”) Univo Pharmaceutical Industries Ltd. ("UNIVO"), a public company whose shares ar

1mo agoYahoo Finance

Beyond Air (XAIR) Q1 2027 Earnings Call Transcript

Detailed price information for Beyond Air Inc (XAIR-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Also Discussed

Investors talking about XAIR also mention

#	Name	Attention
1	Nuvectis Pharma, Inc.NVCT	0%0
2	Axsome Therapeutics IncAXSM	0.01%0
3	Pavmed Inc.PAVM	0%0
4	AVDL - Avadel Pharmaceuticals plc	——
5	KZR - Kezar Life Sciences, Inc.	——
6	Xeris Biopharma Holdings, Inc.XERS	0.08%+0.06
7	Mereo BioPharma Group plc ADRMREO	0.01%-0.01
8	BioXcel Therapeutics, Inc.BTAI	0%new
9	60 Degrees Pharmaceuticals Inc.SXTP	0%+0
10	TruGolf Holdings, Inc. Class A Common StockTRUG	0%+0

Beyond Air, Inc.

Healthcare
Medical Devices

Beyond Air, Inc. is a clinical-stage medical device and biopharmaceutical company specializing in nitric oxide therapy. Central to its offerings is the LungFit platform, an innovative nitric oxide generator and delivery system that uses patented Ionizer™ technology to produce unlimited, on-demand nitric oxide from ambient air, eliminating the need for traditional gas cylinders. The company’s product range includes LungFit PH for treating persistent pulmonary hypertension in newborns, LungFit PRO targeting viral lung infections like pneumonia and COVID-19, and LungFit GO for at-home treatment of nontuberculous mycobacteria infections. Beyond Air also develops therapeutics such as ultra-high concentration nitric oxide treatments for solid tumors and selective neuronal nitric oxide synthase inhibitors for neurological conditions including autism spectrum disorder. With a commitment to advancing respiratory and neurological healthcare, Beyond Air leverages its innovative technologies to expand treatment options across hospital and home settings, driven by a leadership team with deep clinical and scientific expertise.

Website

Location

900 Stewart Avenue

Garden City, NY, 11530

United States

Social

What share of all stock conversation is about XAIR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% +0	0% 0

Sep 1

Beyond Air, Inc.'s (XAIR) LungFit GO has been granted Breakthrough Device Designation by the U.S. FDA for treating nontuberculous mycobacterial pulmonary disease.
The company's low float has raised concerns, with some speculating it may lead to a significant price drop.
There is ongoing discussion about the potential dilution of shares and the impact of warrants, with some investors predicting a price under $1.00.

Generated by AI

Sentiment

Of the messages about XAIR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	40%	50.53% -9.97	73.38% -2.1
Bearish	—	60%	49.47% +9.97	26.62% +2.1

Bullish· Aug 31

The FDA approval of Beyond Air, Inc. (XAIR) is a significant news event that could trigger a reversal and a subsequent price increase.
The asset has seen a trend reversal, with big investors coming in and algos accumulating shares, indicating a strong uptrend.
The company's stock price is expected to reach $9 or higher, with some predictions as high as $11, driven by funds buying and short covering.

Bearish· Aug 31

The company's stock price has dropped significantly despite positive news, including a FDA announcement, and the author believes this is a result of intentional dilution.
The company's dilution of shares, including millions of warrants, has been identified as a major red flag, and the author believes this is a scam to manipulate the stock price.
The company's stock has been shorted despite positive news, and the author believes this is a sign of the market's distrust in the company's fundamentals, with the stock experiencing a 52-week low.

Generated by AI

Topics

Of the messages about XAIR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	71.43%	30.3%	16.54%
Technical Analysis	—	28.57%	69.7%	33.69%
Analysts	—	0%	0%	23.14%
Controversies	—	0%	0%	1.06%
Earnings	—	0%	0%	0.68%
Macro	—	0%	0%	24.89%

Announcements· Jan 14

Beyond Air, Inc. announced the sale of 85% of its subsidiary NeuroNOS, a developer of a groundbreaking medical treatment, for $36 million.
Beyond Air received FDA approval and CE Mark for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure.
Beyond Air announced a $5.0 million private placement of 3,930,818 shares and warrants at a combined price of $1.272 per share, priced at-the-market under Nasdaq rules.

Technical Analysis· Jan 14

The technical analysis suggests that Beyond Air, Inc. ($XAIR) is in a long-term downtrend, with a parabolic squeeze off lows and extremely stretched momentum, indicating a high risk of mean reversion.
The stock has shown a significant vertical move, with a 150% increase on high relative volume, suggesting a massive institutional accumulation phase and a potential structural trend shift.
The 1-hour chart for $XAIR has confirmed a Wave 5 correction, with a potential base forming before a potential Wave (b) relief toward $2.13, and the stock is technically oversold with a golden cross on the 5-minute chart.

Generated by AI

Community

Of the messages about XAIR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	28%	41.03%	15.24%
Newcomers	—	72%	58.97%	84.76%

Regulars· Aug 31

The FDA Breakthrough Device Designation for LungFit GO to treat Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) has been a significant catalyst for the stock, with many regular participants noting its importance.
Several participants have expressed their bullish sentiments on the stock, with some even initiating or re-initiating their buy positions, citing the company's potential for growth.
The stock has been subject to short selling and volatility, with some participants warning others to sell the "pops" and buy the dips, rather than chasing the stock's price movements.

Newcomers· Aug 31

Many newcomers are optimistic about Beyond Air, Inc. (XAIR), with some predicting a significant price increase after a positive press release.
Some newcomers believe that XAIR's recent price drop is a buying opportunity, with one user predicting a reversal and another stating that major news will drive the stock up.
However, others are skeptical, pointing out concerns such as the company's history of losses, lack of FDA approval, and potential dilution from resale shares and warrants.

Generated by AI

Beyond Air

Social

Sep 1

Bullish· Aug 31

Bearish· Aug 31

Announcements· Jan 14

Technical Analysis· Jan 14

Regulars· Aug 31

Newcomers· Aug 31

Beyond Air at cantors conference: generation 2 is the focus

Beyond Air to Participate in the 2026 Cantor Global Healthcare Conference

Beyond Air® Receives FDA Breakthrough Device Designation for LungFit® GO to Treat Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD)

Beyond Air to sell NeuroNOS stake to Univo for 19.99% equity

Beyond Air Enters Definitive Agreement to Sell Its NeuroNOS Stake to UNIVO Pharmaceutical Industries in Exchange for Equity and Milestone Payments

Beyond Air (XAIR) Q1 2027 Earnings Call Transcript

Also Discussed

Beyond Air, Inc.

Company Information

Location

Beyond Air at cantors conference: generation 2 is the focus

Beyond Air to Participate in the 2026 Cantor Global Healthcare Conference

Beyond Air® Receives FDA Breakthrough Device Designation for LungFit® GO to Treat Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD)

Beyond Air to sell NeuroNOS stake to Univo for 19.99% equity

Beyond Air Enters Definitive Agreement to Sell Its NeuroNOS Stake to UNIVO Pharmaceutical Industries in Exchange for Equity and Milestone Payments

Beyond Air (XAIR) Q1 2027 Earnings Call Transcript

Also Discussed

Social

Sep 1

Bullish· Aug 31

Bearish· Aug 31

Announcements· Jan 14

Technical Analysis· Jan 14

Regulars· Aug 31

Newcomers· Aug 31